Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charleston, Daiichi Complete Pharmacokinetics Study | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Charleston, Daiichi Complete Pharmacokinetics Study

CL-108 demonstrates comparable bioavailability in pain indication

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charleston Laboratories, Inc. and co-development and commercialization partner, Daiichi Sankyo, Inc., have completed a pharmacokinetics study on CL-108, Charleston’s lead product in development for moderate to severe pain and the prevention of opioid-induced nausea and vomiting.
 
CL-108 is a tablet containing 7.5 mg of hydrocodone and 325 mg of acetaminophen with 12.5 mg of fast-absorbed promethazine. 
 
“This study demonstrated that CL-108 provides comparable bioavailability of hydrocodone, acetaminophen and promethazine to commercial products,” said Dr. Bernard Schachtel, chief scientific officer at Charleston Laboratories.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics